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I. INTRODUCTION

Each year since 1980, on a Friday in January, the Massachusetts
Institute of Technology (“MIT”) has hosted the MIT Mystery Hunt.2 To
win this competition, a team must solve a number of challenging puzzles
whose solutions reveal where on the MIT campus to find a special coin.
The first team to locate the coin wins the Mystery Hunt and is awarded
the privilege of designing the next Mystery Hunt.
In 2005, the clues of one of the puzzles, entitled “Shotgun Wedding,”
involved 11 nucleotide sequence fragments, each approximately 1,000
nucleotides in length.3 To solve this puzzle, it was necessary to
understand that the fragments resulted from “shotgun sequencing,” a
©
2011 Andrew W. Torrance
*
Andrew W. Torrance is a Professor in the School of Law, a Research Associate at the
Biodiversity Institute, and a Docking Faculty Scholar at the University of Kansas. He
received a Ph.D. in biology from Harvard University and a J.D. from Harvard Law School.
The author would like to thank his research assistants, Dr. James McParland and Dr.
Sparkle Ellison, for their invaluable assistance with research for this article.
1
The author first presented his ideas about DNA copyright in November 2008 in a
speech entitled “Synthesizing Law for Synthetic Biology,” at Biolaw 2.0: Law at the Frontiers
of Biology, at the University of Kansas School of Law. Subsequently, the author presented
his proposals regarding DNA copyright in March 2009 in “Synthetic Biology—Law and the
Next Open Source Hardware,” at the MIT Innovation Lab, MIT Sloan School of
Management; in May 2009 in “Synthesizing Law for Synthetic Biology,” at the OECD
Collaborative Mechanisms for Intellectual Property Management Workshop, OECD
Headquarters, Paris, France; in June 2009 in “Synthesizing Law for Synthetic Biology,” at
the Biotech Summer Institute at Drake University and Pioneer Hi-Bred, Des Moines, Iowa;
in November 2009 in “The Legal Possibilities of Synthetic Biology,” at the MIT Innovation
Lab, MIT Sloan School of Management; in September 2010 in “Open Biological
Innovation—From Patents to Commons to Copyright to Open Source,” at the Berkeley
Open Innovation Forum, Berkeley Law Schools, Berkeley, California; in January 2011 in
“Synthetic Biology Meets the Law,” at the American Association of Law Schools Annual
Meeting, San Francisco, California; and in March 2011 in “Open Biological Innovation:
From Patents to Commons to Copyright to Open Source,” at the Valparaiso University Law
Review Symposium on Bioethics, Law, and Synthetic Biology, Valparaiso University
School of Law, Valparaiso, Indiana. The author has previously published articles about
gene patents Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11 MINN. J.L.
SCI. & TECH. 157, 157–91 (2010) [hereinafter, Torrance, Gene Concepts, Gene Talk, and Gene
Patents], and Andrew W. Torrance, Patent Rights and Civil Wrongs: The ACLU Lawsuit, 8
BIO-IT WORLD 11 (2009); synthetic biology, Andrew W. Torrance, Synthesizing Law for
Synthetic Biology, 11 MINN. J.L. SCI. & TECH. 157, 642–48 (2010) [hereinafter, Torrance,
Synthesizing Law for Synthetic Biology]; and genomics, Andrew W. Torrance, Family Law and
the Genomic Revolution, 79 U. MO. KAN. CITY L. REV. 271 (2011) that draw on some common
research sources.
2
MIT Mystery Hunt, MIT.EDU, http://web.mit.edu/puzzle/www/index.html (last
visited June 27, 2011). Thank you to James Grimmelmann for bringing this to my attention
on the IPProfs listserv (October 14, 2010).
3
Jed Goldstone, Shotgun Wedding, MIT.EDU, http://web.mit.edu/puzzle/www/05/
setec/shotgun_wedding (last visited June 27, 2011).
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method of determining the sequential nucleotides in a stretch of
deoxyribonucleic acid (“DNA”). The fragments had to be aligned
“contiguously,” and the ends of “contig[s]” translated into their
corresponding amino acids. Done properly, this resulted in the
following instruction: “SEEKGENEFRAMES.” Finally, the longest
“open reading frame[ ],” when translated into its corresponding amino
sequence,
yielded
the
message
“MYANSWERISSEPARATECHECKSANDTHERESTISFILLER.”4
Armed with this clue, teams could progress to the next stage in the
Mystery Hunt.
An intriguing feature of the Shotgun Wedding puzzle is that the
DNA sequences it employed were designed by Jed Goldstone not to be
precursors for the synthesis of a polypeptide that might be useful in
treating disease, conferring a useful trait on a crop plant, or carrying out
an industrial process. Rather, Goldstone simply used the genetic code of
nucleotides adenine (“A”), guanine (“G”), thymine (“T”), and cytosine
(“C”), and the amino acids (for example, methionine (“M”), tyrosine
(“Y”), and alanine (“Ala”)) encoded by triplet codons of these
nucleotides to create a short intelligible message. Goldstone was an
author, his medium was DNA, and his products were original and
expressive literary works. Although Goldstone employed A, G, T, and C
as symbols to represent nucleotides, he might instead have chosen to
compose his work using actual nucleotides decipherable through routine
chemical sequencing techniques. Either way, the original work of
authorship that Goldstone created in a tangible medium of expression
using sequences of nucleotides and amino acids is eligible for copyright
protection. In fact, even DNA sequences that code for functional
polypeptides or RNAs may qualify for copyright protection to the extent
that function does not dictate structure, and expression is not unduly
constrained.
The idea of DNA copyright is not new. 5 As long ago as 1982, Irving
Kayton concluded that copyright protection is available for DNA. 6 Since
then, several other authors have similarly concluded that DNA
constitutes subject matter eligible for copyright. 7 However, as Rebecca

Id.
In this article, the discussion explicitly focuses on the applicability of copyright law to
DNA. However, this discussion is also germane to RNA, a similar and related nucleic acid,
and polypeptides, which are functionally related to both DNA and RNA.
6
Irving Kayton, Copyright in Living Genetically Engineered Works, 50 GEO. WASH. L. REV.
191, 191–92 (1982).
7
Dan L. Burk, Copyrightability of Recombinant DNA Sequences, 29 JURIMETRICS J. 469, 531–
32 (1988–89); Jorge A. Goldstein, Copyrightability of Genetic Works, 2 BIO/TECHNOLOGY 138
4
5

Produced by The Berkeley Electronic Press, 2011

Valparaiso University Law Review, Vol. 46, No. 1 [2011], Art. 1

4

VALPARAISO UNIVERSITY LAW REVIEW

[Vol. 46

Eisenberg observed in 1990, “copyright protection for DNA sequences
has failed to make its mark outside the scholarly literature.” 8 Since then,
this situation may have begun to change.
In 2002, an organization called the DNA Copyright Institute began to
advertise a service involving the “copyrighting” of a person’s genome to
guard against infringement or misappropriation by others. 9 However
unlikely it is that an existing naturally occurring genome could
constitute a work of authorship, the idea of DNA copyright has begun to
gain traction, especially with respect to partially or fully synthesized
genes or other DNA sequences.10 Improvements in methods of gene
sequencing and gene synthesis have transformed the prospect of
designer DNA from laborious and unpredictable to routine and certain.
Furthermore, the burgeoning field of synthetic biology is founded, at
least in part, on the promise of deliberately engineering genes, cells, and
organisms de novo. In fact, the use of DNA copyright has already begun
in industry. Illumina, Inc., a biotechnology firm whose genome
sequencing machines lead the genomics industry, 11 produces DNA
molecules to be used with its machines, and views their molecules as
works of genetic authorship. Moreover, Illumina explicitly asserts
copyright protection over some of its DNA sequences. To illustrate, the
following is a letter sent to an Illumina customer:
Dear Customer,
This communication is in response to your request for
particular oligonucleotide sequences for use with the
Illumina Genome Analyzer and associated assays.
Below please find the oligonucleotide sequences that we
can make available to you. This communication is solely
for your use and should not be distributed outside your
institution.
(1984); Donna Smith, Comment, Copyright Protection for the Intellectual Property Rights to
Recombinant Deoxyribonucleic Acid: A Proposal, 19 ST. MARY’S L.J. 1083, 1096–1108 (1988).
8
Rebecca Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 721 n.3 (1990).
9
Peter Huck, How the Rich and Famous will Fight to Stay Unique, SUNDAY TRIB. (Mar. 28,
2010),
http://tribune.maithu.com/article/2001/oct/14/how-the-rich-and-famous-willfight-to-stay-unique/.
10
In this article, “gene” and “DNA sequence” are often used interchangeably, where
appropriate. However, DNA sequences constitute the broader, more inclusive category.
Genes fall within one particular category of DNA sequences, while there are many other
types of DNA sequences that are not genes.
11
See Fact Sheet, ILLUMINA.COM, http://www.illumina.com/Documents/company/
IlluminaCorporateSheet_050410.pdf (last visited July 17, 2011) (claiming Illumina, Inc. is a
“leading developer, manufacturer, and marketer of life science tools and integrated
systems for large-scale analysis of genetic variation and function.”).
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The oligonucleotide sequences are protected by
copyright which is owned by Illumina. Illumina allows
you to reproduce the oligonucleotide sequences for use
with the Illumina Genome Analyzer and associated
assays. Additionally, Illumina realizes customers may
need to make alterations to the oligonucleotide
sequences that are necessary to allow use with the
Illumina Genome Analyzer and associated assays. Thus,
Illumina allows you to make such necessary alterations
to the oligonucleotide sequences but only for use with
the Illumina Genome Analyzer and associated assays.
Illumina grants you no other rights to use, reproduce or
otherwise disclose the oligonucleotide sequences.
Alteration or modification of the oligonucleotide
sequences for use with non-Illumina products is not
allowed.
If you reproduce the oligonucleotide sequences for
viewing within your institution, the following copyright
notice must remain affixed to the sequences:
Oligonucleotide sequences © 2006 Illumina, Inc.
All rights reserved. Illumina customers may
reproduce and create derivative works of the
oligonucleotide sequences but only for use with
the Illumina Genome Analyzer and associated
assays. All other uses are strictly prohibited.
If you reproduce these oligonucleotide sequences for
viewing outside your institution (e.g. journal
publication), you must affix the following copyright
notice to the sequences:
Oligonucleotide sequences © 2006 Illumina, Inc.
rights reserved.12

All

Like Goldstone, Illumina designed the oligonucleotides referenced in
the above letter. The nucleotide sequences of the primers and adapters
are not copies of genomic DNA sequences; they are synthetic sequences
12
Letter from Illumina for Customers (Oct. 13, 2010), available at http://www.bioinfo.
uh.edu/IMDSC/Release_of_Oligo_Sequences_Letter_for_Customers1.pdf. Thank you to
Jessica Sibley for bringing this to my attention on the IPProfs listserv.
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not found in nature.13 In fact, it is probably important that they not be
genomic DNA sequences, because, if they were, they might hybridize
with complementary DNA sequences loaded onto Illumina sequencing
machines. Rather, these synthetic sequences must employ designs that
ensure their compatibility with machines sold by Illumina. The Illumina
customer letter indicates that the company considers its authored
oligonucleotides to be protected by copyright. Although these Illumina
sequences may possess more functionality than those composed by
Goldstone, Illumina is correct in its assumption that authored synthetic
DNA sequences are eligible for copyright protection. 14
This Article suggests that DNA—especially synthetic DNA—
constitutes eligible subject matter for copyright protection under the
Copyright Act. Although DNA has long been copyrightable, in theory,
the movement towards synthetic DNA in biotechnology has further
strengthened existing arguments in favor of DNA copyright. Section II
of this Article illustrates some of the features of DNA that suit it for
copyright protection by tracing the conceptual evolution of DNA from
factor to program. Section III suggests the usefulness of DNA copyright
through a discussion of the recent rocky road down which gene patents
have been traveling. Section IV sketches the rise of synthetic biology as a
distinct field. Section V outlines why DNA is eligible for copyright
protection, considers implications of DNA copyright, and then discusses
benefits that might accrue to society under a DNA copyright regime,
including those flowing from fair use provisions and the fostering of
open source biology. The Article concludes by suggesting that DNA
copyright: (1) already exists; (2) provides an alternative to DNA
patenting; and (3) may provide a number of societal benefits in terms of
biological innovation and improved societal access to the fruits of such
innovation.
II. EVOLVING CONCEPTS OF DNA
Few concepts in science have undergone such rapid and complete
transformation as the concept of the unit of heredity. At various times in
Rochelle Dreyfuss, IPProfs Listserv (Oct. 14, 2010).
The United States Copyright Office appears to have acknowledged the
copyrightability of DNA in 1987. See J. SIGALOS, INTELLECTUAL PROPERTY PROTECTION FOR
BIOTECHNOLOGY INNOVATIONS 13 (1987) (stating the “Copyright Office advises drawing of
DNA nucleotide sequence bearing copyright notice sufficient for copyright”). But see
OFFICE OF TECH. ASSESSMENT, OTA-BA-370, NEW DEVELOPMENTS IN BIOTECHNOLOGY:
PATENTING LIFE—SPECIAL REPORT 43 (1989) (noting that the Copyright Office’s unofficial
position that nucleic acid sequences are not copyrightable, citing Peter R. Bahn & Steven J.
Hultquist, Engineered Proteins as Intellectual Property, GENETIC ENGINEERING NEWS, Mar.
1987, at 18–19).
13
14
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history, what is often called the “gene” was believed to be a spirit, a
liquid, or a particle. Now, the gene is generally conceived of as a stretch
of DNA capable of encoding information, which, in turn, is capable of
acting as a template for constructing complementary sequences of DNA,
RNA (directly), or polypeptides (indirectly). Apart from some viral
RNA genomes, genes in nature are usually composed of DNA.
Often only a fraction of the DNA in genes encodes “exons” and is
expressed as mRNA and by extension, polypeptide products. 15 In fact,
non-expressed DNA, or “introns,” in mammals, insects, and birds
comprise about 80% of the nucleotide length of a gene. 16 Moreover, the
vast majority of the human genome—about 98%—does not encode
polypeptides.17 Noncoding and apparently nonfunctional DNA has
been dismissively termed “junk DNA.” Much of this noncoding DNA
may eventually be discovered to possess functionality, but it appears
likely that much of the DNA in the genomes of humans and other
organisms may lack direct function.
As the understanding of DNA has evolved over the last century, so
have the economic and legal treatments of DNA. From the beginnings of
the biotechnology industry in the 1970s, many have sought to attach
intellectual property protection to DNA and related molecules. The
protection offered by trade secrecy depends on the extent to which the
molecule to be protected is disclosed by the product or service of which
it forms a part, but is agnostic about how exactly science conceives of
that molecule. The aptness of patent protection for DNA increased as
the conception of genes underwent a transition from inchoate factors to
discrete molecules. Patent protection for DNA seemed assured in 1980
by the landmark Supreme Court decision in Diamond v. Chakrabarty.18
However, patent protection for DNA isolated from genomic sources has
lately been put into doubt by the Southern District of New York’s
decision in Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office,
and remains in doubt following the Second Circuit’s ruling on the case.19
As the conception of DNA shifted again from a mere physical molecule
to a repository of information and instructions, copyright became a more
BENJAMIN LEWIN, GENES IX 45 (2008).
Id.
17
Greg Elgar & Tanya Vavouri, Tuning in to the Signals: Noncoding Sequence Conservation
in Vertebrate Genomes, 24 TRENDS GENETICS 344, 345 (2008).
18
Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
19
Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181
(S.D.N.Y. 2010) (holding that patents on DNA that indicate breast cancer susceptibility
were invalid). On July 29, 2011, the Federal Circuit reversed the Southern District of New
York’s decision in part and affirmed in part. Ass’n for Molecular Pathology v. U.S. Patent
& Trademark Office, 2011 WL 3211513 (Fed. Cir. July 29, 2011).
15
16
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promising source of intellectual property protection. To understand the
transition in intellectual property eligibility, it is important to trace how
the conception of genes and DNA has evolved.
A. Factor
One of the signal achievements of Charles Darwin was the idea that
evolution occurs by means of “descent with modification.” 20 However,
Darwin did not determine the specific mechanism by which
modifications were passed along from ancestors to descendants. Rather,
as suggested by the title of his masterwork, The Origin of Species by Means
of Natural Selection, he identified natural selection as a higher order cause
of evolutionary change. What Darwin did contribute was speculation
about the existence of “gemmules” as the specific units of heredity. 21
At about the same time, an Austrian monk named Gregor Mendel
had formed a hypothesis that plant traits were passed from parents to
offspring by means of “Elemente.”22 Through carefully controlled
experiments on pea plants, Mendel not only demonstrated the efficacy of
his Elemente hypothesis, but also elucidated the basic rules of heredity. 23
Mendel’s foundational research came to prominence only after it was
published in English in 1901.24
Neither Darwin’s “gemmules” nor Mendel’s “Elemente” survived as
a description of the unit of heredity. That distinction went instead to the
“gene,” a word coined by Wilhelm Johannsen and inspired by
“pangens,” a word coined by Hugo de Vries. 25 The word “gene” rapidly
rose to dominance as a description of the fundamental unit of heredity.
B. Particle
The unit of heredity gradually underwent a transition from a vague
factor of unknown form to a discrete and physical object. In the 19th
century, August Weismann proposed the existence of “determinants,”
which he imagined to be particles of “a definite chemical, and above all,
CHARLES DARWIN, ON THE ORIGIN OF SPECIES BY MEANS OF NATURAL SELECTION 456
(Harvard Univ. Press 1966) (1859).
21
See EVELYN FOX KELLER, THE CENTURY OF THE GENE 2 (2000) (explaining Darwin’s
impact on the understanding of genes).
22
Id. at 19.
23
See generally Gregor Mendel, Experiments in Plant Hybridisation, 26 J. ROYAL
HORTICULTURAL SOC’Y 1 (1901) (proving that certain pairs of differentiating characters, the
germ-cells of a hybrid, or cross-bred, are pure, being carriers and transmitters of either the
one character or the other, not both).
24
Id.
25
KELLER, supra note 21, at 1–2.
20
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molecular composition.”26 His views were echoed by his contemporary,
Hugo de Vries, who insisted that “[j]ust as physics and chemistry go
back to molecules and atoms, the biological sciences have to penetrate to
these units in order to explain, by means of their combinations, the
phenomena of the living world.”27 In addition to clarifying the
mechanisms of heredity, understanding the particulate nature of
hereditary units facilitated the growth of experimental genetics.
In the “Fly Room” at Columbia University, Thomas Hunt Morgan
used the fruit fly (Drosophila melanogaster) as a model organism for
experimental genetics.28 Among other accomplishments, Morgan was
able to demonstrate that genes reside on chromosomes, and in his book
entitled The Theory of the Gene, he described the orientation of genes on
chromosomes as “beads on a string.”29 Due largely to Morgan, whose
research won him the 1933 Nobel Prize in Medicine, “genes became
generally viewed as discrete, stable, independently segregating units of
inheritance lined up along a chromosome, an image captured by the
most commonly invoked metaphor—that of ‘beads on a string.’” 30
However, if they can be viewed as particles, genes are very peculiar
particles that encode remarkable amounts of information.
C. Molecule
By the middle of the 20th century, the idea that genes consisted of
discrete particles had become firmly entrenched in biology. However,
the precise structural and functional nature of these particles had not yet
been elucidated. Both polypeptides and nucleic acids, such as DNA, had
been proposed as the carriers and determinants of hereditary traits. The
scales tipped decisively in favor of DNA following the Avery-MacLeodMcCarty experiment. In 1943, two Canadians, Oswald Avery and Colin
MacLeod, and an American, Maclyn McCarty, experimentally
determined that bacterial genes were composed of DNA, which “must
be regarded not merely as structurally important but as functionally
active in determining the biochemical activities and specific

26
August Weismann, The Continuity of the Germ-Plasm as the Foundation of a Theory of
Heredity, in ESSAYS UPON HEREDITY AND KINDRED BIOLOGICAL PROBLEMS 167, 168 (Edward
B. Poulton et al. eds., 1891).
27
HUGO DE VRIES, INTRACELLULAR PANGENESIS 13 (C. Stuart Gager trans., The Open
Court Publishing Co. 1910) (1889).
28
See JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE 12–14 (Beth Wilbur et
al. eds., 6th ed. 2008).
29
THOMAS HUNT MORGAN, THE THEORY OF THE GENE 24 (1928).
30
Leonie Moyle, Most Ingenious: Troubles and Triumphs of the Century of Genes, 17
BIOLOGY & PHIL. 715, 715–16 (2002).
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characteristics of pneumococcal cells.”31 Alfred Hershey and Martha
Chase later confirmed this discovery in blender experiments using
bacteria and bacteriophage.32 The vague concept of a gene as a physical
particle had been married to a specific molecule: DNA.
D. Sequence
In 1953, James Watson and Francis Crick announced that they had
discovered the physical conformation of DNA: two individual DNA
molecules wind around each other in antiparallel to form a double
helix.33 As Watson and Crick explained:
In the double helix, the two DNA chains are held
together by hydrogen bonds . . . between pairs of bases
on the opposing strands . . . . This base pairing is very
specific: the purine adenine only base-pairs to the
pyrimidine thymine, whereas the purine guanine only
base-pairs to the pyrimidine cytosine. In double-helical
DNA, the number of A residues must be equal to the
number of T residues, whereas the number of G and C
residues must likewise be equal . . . . As a result, the
sequence of the bases of the two chains of a given double
helix have a complementary relationship, and the
sequence of any DNA strand exactly defines that of its
partner strand.34
This announcement “convinced biologists not only that genes are real
molecules but also that they are constituted of nothing more mysterious
than deoxyribonucleic acid.”35 Building on the insight of the double
helix, Seymour Benzer was soon able to demonstrate that genes were
linear stretches of DNA sequence.36
Once DNA had been understood to comprise linear arrays of
nucleotides, much research was devoted to determining the exact
nucleotide sequences of DNA molecules of interest. At first, these efforts
were laborious and inefficient. Early sequencing efforts relied on
restriction enzymes, which are proteins capable of snipping a DNA
31
Oswald T. Avery et al., Studies on the Chemical Nature of the Substance Inducing
Transformation of Pneumococcal Types, 79 J. EXPERIMENTAL MED. 137, 155 (1944).
32
See generally A. D. Hershey & Martha Chase, Independent Functions of Viral Proteins and
Nucleic Acid in Growth of Bacteriophage, 36 J. GEN. PHYSIOLOGY 39 (1952).
33
WATSON ET AL., supra note 28, at 22.
34
Id.
35
KELLER, supra note 21, at 3.
36
Id. at 52.
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molecule at sites characterized by specific patterns of nucleotides.
Restriction enzymes can be employed to recognize locations in the
genome hosting particular nucleotide motifs. 37 However, by the 1970’s,
sequencing methods had improved so substantially that one could
identify the precise pattern of individual nucleotides in a DNA molecule.
These methods worked as follows:
The underlying principle of DNA sequencing is based
on the separation, by size, of nested sets of DNA
molecules. Each of the DNA molecules starts at a
common 5' end, and terminates at one of several
alternative 3' endpoints. Members of any given set have
a particular type of base at their 3' ends. Thus, for one
set, the molecules all end with a G, for another a C, for a
third an A, and for the final set a T. Molecules within a
given set (e.g., the G set) vary in length depending on
where the particular G at their 3' end lies in the
sequence.
Each fragment from this set therefore
indicates where there is a G in the DNA molecule from
which they were generated.38
Allan Maxam and Walter Gilbert invented one of the leading methods,
known as “Maxam-Gilbert sequencing,” which used “four different
regimens of chemical treatment that cause [radiolabeled DNA molecules]
to break preferentially at Gs, Cs, Ts, or As.”39 Frederick Sanger invented
the other leading method, called the “[Sanger] chain-termination
method,” which used the enzyme DNA polymerase to create
complementary copies of fragments of the DNA molecule being
sequenced.40 Gilbert and Sanger shared the 1980 Nobel Prize in
chemistry “for their contributions concerning the determination of base
sequences in nucleic acids.”41 Further improvements in sequencing have
made the determination of DNA sequences from all biological sources
routine. Even entire genomes, such as those of humans, have been

ANTHONY J. F. GRIFFITHS ET AL., INTRODUCTION TO GENETIC ANALYSIS 343–60 (2005).
WATSON ET AL., supra note 28, at 753.
39
Id. at 754; see Allan M. Maxam & Walter Gilbert, A New Method for Sequencing DNA, 74
PROC. NAT’L ACAD. SCI. U.S.A. 560 (1977).
40
WATSON ET AL., supra note 28, at 754.
41
See Bo G. Malmstrom, The Nobel Prize for Chemistry (1980), in NOBEL LECTURES:
CHEMISTRY 377–432 (Tore Frängsmyr & Sture Forsén 1980).
37
38
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sequenced.42 Consequently, the total amount of known DNA sequence
information forms an ever growing mountain of data.
E. Information
Long before the discovery of the DNA double helix, Archibold
Garrod suggested that “genes work by controlling the synthesis of
specific enzymes.”43 Employing Neurospora fungus as a model organism,
George Beadle and Edward Tatum were able to confirm this “[O]ne
[G]ene-[O]ne [E]nzyme [H]ypothesis” by demonstrating that “one gene
controlled a single chemical reaction, which in turn was regulated by a
specific enzyme.”44 This led to the parsimonious inference that “genetic
information within genes determines the order of the 20 different amino
acids within the polypeptide chains of proteins.” 45
Close on the heels of announcing the DNA double helix, Watson and
Crick published the “Genetical Implications of the Structure of
Deoxyribonucleic Acid,” in which they postulated that the DNA
sequence of a gene corresponded precisely to the amino acid sequence of
a corresponding polypeptide.46 In 1958, Crick elaborated on this
hypothesis, proposing that “the specificity of a piece of nucleic acid is
expressed solely by the sequence of its bases, and that this sequence is a
(simple) code for the amino acid sequence of a particular protein.” 47
The first to crack part of the genetic code were Marshall Nirenberg
and Heinrich Matthaei, who “observed in 1961 that the addition of the
synthetic polynucleotide poly U (UUUUU . . . ) to a cell-free system
capable of making proteins leads to the synthesis of polypeptide chains
containing only the amino acid phenylalanine. The nucleotide groups
UUU thus must specify phenylalanine.”48 This discovery set off a race to
break the rest of the genetic code, and “[b]y 1967 the code was essentially
completed.”49 Understanding DNA as encoding information via a
specific language of codons revealed a duality in the nature of genes and
DNA: they were simultaneously physical and informational. The
42
See, e.g., E. S. Lander et al., Initial Sequencing and Analysis of the Human Genome, 409
NATURE 860 (2001); J. Craig Venter et al., The Sequence of the Human Genome, 291 SCI. 1304
(2001).
43
WATSON ET AL., supra note 28, at 19.
44
LILY E. KAY, WHO WROTE THE BOOK OF LIFE 52 (2000).
45
WATSON ET AL., supra note 28, at 19.
46
J. D. Watson & F. H. C. Crick, Genetical Implications of the Structure of Deoxyribonucleic
Acid, 171 NATURE 964, 964 (1953).
47
F. H. C. Crick, On Protein Synthesis, 12 SYMP. SOC’Y FOR EXPERIMENTAL BIOLOGY 138,
152 (1958) [hereinafter On Protein Synthesis].
48
WATSON ET AL., supra note 28, at 37.
49
KAY, supra note 44, at 330.
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informational nature of DNA separates it qualitatively from other
molecules. Consequently, “[t]he human genome is now generally
viewed as an information system and, more specifically, as a ‘Book of
Life’ written in the language of DNA, or DNA code, to be read and
edited.”50
F.

Program

In his famous summation of genetics, Crick once remarked that
“DNA makes RNA, RNA makes protein, and proteins make us.” 51
Elaborating on this simple recipe, François Jacob and Jacques Monod
suggested that “the genome contains not only a series of blue-prints, but
a co-ordinated program of protein synthesis and the means of
controlling its execution.” 52 Jacob and Monod uncovered a complex
network of interacting genetic elements that came to be known as the
“operon” model of gene regulation. 53 This operon model suggested a
“genetic program,” comprising, as it did, “a linked cluster of regulatory
elements and structural genes whose expression is coordinated by the
product of a regulator gene situated elsewhere in the genome.”54
James Bonner expanded on the concept of a genetic program in his
1965 book entitled The Molecular Biology of Development. Bonner
deliberately drew a close analogy between computers and cells. He
described a hierarchy of programs, including a “‘master programme
constituted in turn of a set of subprogrammes or subroutines,’” 55 with
the latter further subdivided into “a list of cellular instructions or
commands.”56
Although organisms and their cells are not electronic computers, and
genes are not written in software code, the similarities are striking. In
fact, one of the major goals of synthetic biology is “to create a
programmable microorganism from scratch.”57

Id. at 1.
KELLER, supra note 21, at 54.
52
François Jacob & Jacques Monod, Genetic Regulatory Mechanisms in the Synthesis of
Proteins, 3 J. MOLECULAR BIOLOGY 318, 354 (1961).
53
See LEWIN, supra note 15, at 858 (“An operon is a unit of bacterial gene expression and
regulation, including structural genes and control elements in DNA recognized by
regulator gene product(s).”).
54
KAY, supra note 44, at 57.
55
Id. at 85, 134.
56
Id. at 85–86.
57
Arjun Bhutkar, Synthetic Biology: Navigating the Challenges Ahead, 8 J. BIOLAW & BUS.
19, 20 (2005).
50
51
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III. PATENT PROTECTION FOR DNA
A. Origin
During 1973 and 1974, Stanley Cohen and Herbert Boyer invented a
method for removing a specific fragment of DNA from one organism
and introducing it into the genome of a different organism. 58
Significantly, they received a patent for their invention, which was
entitled “Process for producing biologically functional molecular
chimeras.”59 This method proved to be important to modern molecular
biology and foundational to the biotechnology industry. Within several
years, biologists had genetically engineered the eubacterium, Escherichia
coli, successfully to express the gene encoding the human hormone
somatostatin.60 Of similar importance to the development of the
biotechnology industry was a legal decision about a patent application
filed by Dr. Ananda Chakrabarty in 1972. Rather than claim a method,
this patent application involved a genetically modified organism.
Among other inventions claimed in the patent application was a
“human-made, genetically engineered bacterium . . . capable of breaking
down multiple components of . . . oil.”61 In 1980, the United States
Supreme Court upheld the patentability of “[a] bacterium from the
genus Pseudomonas containing therein at least two stable energygenerating plasmids.”62 Not only did the Supreme Court appear to
support the patentability of organisms, it also appeared to approve of the
patentability of isolated DNA. Biotechnology began advancing rapidly
on both scientific and legal fronts.
Complex biological molecules—such as DNA, RNA, and
polypeptides—became the subject of patent claims beginning in the early
1970s. Previously, patents had successfully claimed methods that
involved polypeptides and proteins, but in 1971, composition claims
were issued for a polypeptide in U.S. Patent Number 3,607,370,63 and for
a protein in U.S. Patent Number 3,619,206.64 Additionally, in 1972, a
composition claim for a peptide was issued in U.S. Patent Number
58
Sally Smith Hughes, Making Dollars Out of DNA—The First Major Patent in
Biotechnology and the Commercialization of Molecular Biology, 1974–1980, 92 ISIS 541, 541
(2001).
59
U.S. Patent No. 4,237,224 (filed Nov. 4, 1974).
60
Keiichi Itakura et al., Expression in Escherischia Coli of a Chemically Synthesized Gene for
the Hormone Somatostatin, 198 SCI. 1056 (1977).
61
Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980).
62
U.S. Patent No. 4,259,444 (filed June 7, 1972) (emphasis added).
63
Pressure-Sensitive Adhesive Tape Comprising Gluten Hydrolypate Derivatives, U.S.
Patent No. 3,607,370 (filed May 29, 1969).
64
Modified Proteins, U.S. Patent No. 3,619,206 (filed May 21, 1969).
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3,645,689.65 A similar progression occurred for DNA and genes. A
patent claim including “DNA” was issued in 1973,66 the word “gene”
occurred in an issued claim in U.S. Patent Number 3,710,511,67 and 1978
saw the issuance of claims in U.S. Patent Number 4,116,770 that were
directed to phenotypic traits encoded by specific genes.68 However, it
was not until two years after the decision in Diamond v. Chakrabarty that
U.S. Patent Number 4,363,877 was issued with composition claims that
included genes, in this case encoding growth hormone polypeptide. 69
These claims were the first to cover genes themselves, 70 which encoded
“[h]uman chorionic somatomammotropin” and “the growth hormone of
an animal species.”71
After the Diamond v. Chakrabarty decision in 1980, patent
applications, with a necessary lag time, issued patents claiming genes
and DNA rose rapidly. Annual filings of patent applications rose from
hundreds in 1984 to thousands from the mid-1990s to the early 2000s.72
Annual patent issuances rose from hundreds in the late 1980s to
thousands during the late 1990s until the late 2000s.73
B. Effect
Patent protection affords patent owners the right to exclude others
from making, using, offering to sell, or selling patented genes within the
United States. In addition, patent owners can prevent others from
importing patented genes into the United States.74 The availability of
patent protection for DNA sequences has played a key role in attracting
investment to the biotechnology industry. In fact, for an industry that
has yet to produce a profit as a whole, patent portfolios covering genes
may constitute one of the most valuable assets owned by biotechnology

Method and Apparatus for Analyzing Proteins, U.S. Patent No. 3,645,689 (filed Apr. 9,
1970).
66
Diagnostic Method Utilizing Synthetic Deoxyrilionucleotide Oligomer Template, U.S.
Patent No. 3,755,086 (filed Feb. 9, 1971).
67
Procedures for Use of Genic Male Sterility in Production of Commercial Hybrid
Maize, U.S. Patent No. 3,710,511 (filed Apr. 21, 1971).
68
Waxy Barley Starch with Unique Self-Liquifying Properties, U.S. Patent No. 4,116,770
(filed Feb. 27, 1975).
69
Recombinant DNA Transfer Vectors, U.S. Patent No. 4,363,877 (filed Apr. 19, 1978).
70
Gene Patents and Global Competition Issues—Protection of Biotechnology Under Patent Law,
GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (Jan. 1, 2006), http://www.genengnews.
com/articles/chitem.aspx?aid=1163&chid=0.
71
Recombinant DNA Transfer Vectors, U.S. Patent No. 4,363,877 (filed Apr. 19, 1978).
72
Torrance, Gene Concepts, Gene Talk, and Gene Patents, supra note 1, at 157–91.
73
Id.
74
35 U.S.C. § 271(a) (2006).
65
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companies.75 Sheila Jasanoff has described various important ways in
which patents have supported the development of biotechnology:
Especially in the United States, patents played a
foundational role in the development of the
biotechnology industry at several levels. First, the
extension of patents to the life sciences created new
classes of property rights in things that were previously
outside the realm of what could be owned, or even
thought of as subject to ownership claims. As a result,
these objects became commodities that could have value,
be exchanged, circulate in markets, and foster
productivity. Second, much of the early development of
biotechnology occurred before there were any
marketable products, and patents were the only
evidence for eager venture capitalists that there might be
something of future value to justify present investment.
Third, patents provided some assurance to jittery
investors that they would not be mired in endless legal
wrangling if commercially useful products ever came on
line. Fourth, patents proved to be a way of sorting out
the competing claims of participants in an increasingly
complex web of invention that linked together the
disparate interests of patients, research subjects, farmers,
academic researchers, universities, start-up firms,
government, and industry.76
In short, patents appear to have played an especially crucial role in
justifying the huge investments in research, development, and
regulatory compliance that biotechnology and pharmaceutical
companies face in discovering gene-based drugs and bringing them to
market.77
See John Golden, Biotechnology, Technology Policy, and Patentability: Natural Products
and Invention in the American System, 50 EMORY L.J. 101 (2001).
76
SHEILA JASANOFF, DESIGNS ON NATURE: SCIENCE AND DEMOCRACY IN EUROPE AND THE
UNITED STATES 203–04 (2005).
77
In their recent study of the role that the patent system plays in spurring innovation,
James Bessen and Michael J. Meurer suggest the patent system may indeed promote
innovation in the pharmaceutical/biotechnology industry. JAMES BESSEN & MICHAEL J.
MEURER, PATENT FAILURE: HOW JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT
RISK 85–88 (2008). As Bessen and Meurer stated, “[t]he evidence certainly is consistent with
the notion that patents encourage American pharmaceutical R&D.” James Bessen &
Michael J. Meurer, Do Patents Stimulate R&D Investment and Promote Growth?, PATENTLYO
BLOG (Mar. 13, 2008), http://www.patentlyo.com/patent/2008/03/do-patents-stim.html.
75
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C. Criticism
Gene patents are not without their critics. Controversy over
patenting DNA is due, in large part, to the fact that even human genes
have been considered eligible for patentable protection. According to a
study by Fiona Murray and Kyle Jensen, approximately 20% of the
known genes in the human genome have been claimed in patents issued
by the United States Patent and Trademark Office (“USPTO”).78 The
ethics of allowing this “‘gold rush’” have been questioned,79 as have the
practical threats to genetic research allegedly posed by the consequent
tragedy of the “[a]nticommons.” 80 More sensational claims misinterpret
the scope of the patent grant, which, in the case of DNA derived from
genomic sources, usually extends only to “isolated” or “purified” DNA.
Nevertheless, Devanand Crease and George Schlich have warned that,
“[t]o the person in the street, the grant of a patent covering all potential
uses of these genes raises the visceral fear of corporate interests claiming
ownership over our very bodies!,” 81 while Michael Crichton raised this
2007 alarm in the New York Times: “YOU, or someone you love, may
die because of a gene patent . . . . Gene patents are now used to halt
research, prevent medical testing and keep vital information from you
and your doctor.”82
Despite the sincerity of these anxieties, the data appears to tell a
different story. In a comprehensive analysis of all human gene patents
identified by Murray and Jensen, Chris Holman found that “not one of
the 4,270 patents in the dataset has ever been found to have been
infringed or been the basis of a preliminary injunction.” 83 Nevertheless,
anxieties over the patenting of DNA appear to have struck a chord with
judges and politicians, and the last several years have presented a
decidedly more hostile atmosphere for DNA patents. Three specific
events exemplify this shift: (1) In re Fisher, (2) the Genomic Research and
78
Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human Genome, 310
SCI. 239 (2005).
79
Tom Hollon, Gene Patent Revisions to Remove Some Controversies, 6 NATURE MED. 362
(2000).
80
Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCI. 698 (1998).
81
Devanand Crease & George Schlich, Is There a Future for ‘Speculative’ Gene Patents in
Europe?, 2 NATURE REVS. DRUG DISCOVERY 407 (2003) (addressing patents claiming the
human genes, BRCA1 and BRCA2, owned by Myriad Genetics, and used to diagnose
propensity for developing breast cancer).
82
Michael Crichton, Op-Ed., Patenting Life, N.Y. TIMES, Feb. 13, 2007, at A2.
83
Christopher M. Holman, The Impact of Human Gene Patents on Innovation & Access: A
Survey of Human Gene Patent Litigation, 76 U. MO. KAN. CITY L. REV. 295, 353–54 (2007)
(emphasis omitted) (citations omitted).
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Accessibility Act (“GRAA”), and (3) Ass’n for Molecular Pathology v. U.S.
Patent & Trademark Office.
D. Response
In 2005, the Court of Appeals for the Federal Circuit heard an appeal
regarding the patentability of fragments of genes called “expressed
sequence tags” (“ESTs”), which are capable of identifying specific DNA
sequences in maize genes.84 The Federal Circuit decided that claims to
these ESTs were invalid because they lacked utility and enablement. In
explaining its decision, the court argued that:
The basic quid pro quo contemplated by the
Constitution and the Congress for granting a patent
monopoly is the benefit derived by the public from an
invention with substantial utility. Unless and until a
process is refined and developed to this point—where
specific benefit exists in currently available form—there
is insufficient justification for permitting an applicant to
engross what may prove to be a broad field.85
Rather than providing a mere benefit in conducting further research, the
court suggested that a claimed invention should provide “some
immediate benefit to the public” in order to be patentable.86 In the wake
of In re Fisher, there was significant uncertainty about what
characteristics, if any, might make a DNA fragment eligible for
patentability. This doubt spread to the patentability of longer stretches
of DNA, including whole genes.
On February 7, 2007, two members of the House of Representatives,
Xavier Becerra (Democrat of California) and Dave Weldon (Republican
of Florida), introduced a bill that would “end[ ] the practice of gene
patenting [including all] genetic material, naturally-occurring or
modified.”87 The bill, the GRAA, would amend the Patent Act by adding
a new section specifically addressing DNA patents. Proposed Section
106 would end the patentability of genes and other DNA sequences by
providing that “[n]otwithstanding any other provision of law, no patent
may be obtained for a nucleotide sequence, or its functions or
correlations, or the naturally occurring products it specifies.” Soon after
its introduction in the House, the GRAA attracted the attention of the
84
85
86
87
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In re Fisher, 421 F.3d 1365, 1367 (Fed. Cir. 2005).
Id. at 1371 (emphasis omitted).
Id. (emphasis omitted) (citation omitted).
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Subcommittee on Courts, the Internet and Intellectual Property. A
hearing called “Stifling or Stimulating: The Role of Gene Patents in
Research and Genetic Testing” was held on October 30, 2007. The
outlook for passage of the GRAA is uncertain. It has not been passed by
either the House or the Senate, and one of its sponsors, Representative
Weldon, is no longer a member of the House.
However, the aims of the GRAA are strikingly congruent to the
results of Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office.
In fact, the decision by Judge Sweet in Ass’n for Molecular Pathology v.
U.S. Patent & Trademark Office appeared to echo Becerra’s assessment of
the patent requirement that DNA must be “isolated and purified” as
“mere wordplay.”88 Sweet similarly described this requirement as a
“lawyer's trick.”89 Furthermore, a proposed last-minute amendment to
the Patent Reform Act of 2011 would have created Section 287(d) to
create a safe harbor provision to limit infringement remedies against
anyone who performs a genetic diagnostic test to give a patient a second
opinion.90 The American Civil Liberties Union (“ACLU”) and its allies
opposed this amendment, fearing that it “would fail to block all patent
holder objections to such testing, fails to address the many other
limitations on scientific research arising out of the issuance of such
patents, and risks allowing gene patent holders to argue that Congress
implicitly endorses the validity of such patents.” 91 Although the
amendment was subsequently withdrawn, it resurfaced in the patent
reform bill that passed the House on June 23, 2011. 92 Obviously, there
continues to be significant Congressional interest in curtailing patents
that claim DNA sequences.
The most important event thus far in darkening the prospects for
DNA patents began on May 12, 2009. The ACLU represented several
female patients as well as a number of sympathetic organizations.
Together, they sued the USPTO, a Utah-based biotechnology firm called
Myriad Genetics, and the Directors of the University of Utah Research
Foundation in the Federal court for the Southern District of New York.

Id.
Ass’n for Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 181, 185 (S.D.N.Y.
2010).
90
Amendment to America Invents Act of 2011, H.R. 1249, 112th Cong. (1st Sess. 2011).
91
Letter from Laura W. Murphy, Dir., Washington Legislative Office, to Chairman
David Dreier, Comm. on Rules, U.S. House of Representatives (June 15, 2011) (on file with
the ACLU).
92
America Invents Act of 2011, H.R. 1249, 112th Cong. (1st Sess. 2011). This bill was
subsequently enacted into law. Leahy-Smith America Invests Act. Pub. L. No. 112-29, 125
Stat. 284.
88
89
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The cause of action in the lawsuit was opposition to the patenting of
human genes and diagnostic uses thereof. 93 The complaint stated:
Every person’s body contains human genes, passed
down to each individual from his or her parents. These
genes determine, in part, the structure and function of
every human body. This case challenges the legality and
constitutionality of granting patents over this most basic
element of every person’s individuality. . . . [as well as
granting patents covering] the concept of looking at or
comparing human genes, and correlations found in
nature between certain genes and an increased risk of
breast and/or ovarian cancer. . . .94
In addition to attracting wide publicity, the ACLU lawsuit surprised
many when it was taken seriously by the court.
The ACLU argued that the patent eligibility of genes posed a direct
and serious threat to those susceptible to breast and ovarian cancers.
Breast cancer afflicts about 13% of women in the United States over their
lifetimes, is newly diagnosed in roughly 200,000 women annually, and is
responsible for about 40,000 deaths per year, making it the third largest
cause of cancer deaths.95 The lifetime risk of developing ovarian cancer
is about 1.7%. However, for carriers of the BRCA (“breast cancer”)
tumor suppressor gene mutations 1 (“BRCA1”) and 2 (“BRCA2”), the
lifetime probability of developing breast cancer and ovarian cancer rises
dramatically to 36–85% and 20–60%, respectively.96 Although knowing
that one has BRCA1 or BRCA2 mutations is terrible news, it does allow
the carrier and her physician to attempt to minimize other risks of
developing cancer. As a result, Myriad Genetics has become a profitable
company by acquiring patents covering both the BRCA1 and BRCA2
mutations and offering genetic tests to detect the presence of these
mutations.97 The ACLU argued that it is immoral to allow Myriad
93
Complaint at 1, 3, Ass’n for Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d
181 (S.D.N.Y 2010) (No. 2010-1406).
94
Id.
95
Breast Cancer, MAYO CLINIC (2011), http://www.mayoclinic.org/breast-cancer/.
96
NORTHWESTERN ASSOCIATION FOR BIOMEDICAL RESEARCH, APPENDIX A2, available at
http://nwabr.org/sites/default/files/learn/bioinformatics/IntroAppendix.pdf
(last
visited Oct. 26, 2011); see also Matthew J. Piehl, The Brave New World of Genetic Biobanks:
International Lessons for a Potential United States Biobank, 46 VAL. U. L. REV. 69, 93–94 (2011)
(describing the harmful effects of the BRCA1 and BRCA2 gene mutations and a woman’s
right not to know she is carrying them).
97
See ENCYCLOPEDIA OF SCIENCE AND TECHNOLOGY COMMUNICATION 331 (Susanna
Hornig Priest ed., 2010) (“The patents offer Myriad Genetics exclusive rights over the
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Genetics to restrict access to such a beneficial diagnostic test by means of
its patents. Myriad Genetics counter-argued that gene patents drove
innovation into diagnostic tests, such as those it offered, by allowing
companies a return on their investments in research, development, and
regulatory approval.
The district court handed ACLU a decisive victory on March 29,
2010. On summary judgment, Judge Sweet held that neither genes nor
genetic tests were eligible for patent protection. In a vigorously worded
opinion, he undermined thirty years of DNA patent practice:
The claims-in-suit directed to “isolated DNA”
containing human BRCA1/2 gene sequences reflect the
USPTO's practice of granting patents on DNA sequences
so long as those sequences are claimed in the form of
“isolated DNA.” This practice is premised on the view
that DNA should be treated no differently from any
other chemical compound, and that its purification from
the body, using well-known techniques, renders it
patentable by transforming it into something distinctly
different in character. Many, however, including
scientists in the field of molecular biology and genomics,
have considered this practice a “lawyer's trick” that
circumvents the prohibitions on the direct patenting of
DNA in our bodies but which, in practice, reaches the
same result . . . . It is concluded that DNA's existence in
an “isolated” form alters neither this fundamental
quality of DNA as it exists in the body nor the
information it encodes. Therefore, the patents at issue
directed to “isolated DNA” containing sequences found
in nature are unsustainable as a matter of law and are
deemed unpatentable subject matter under 35 USC
§ 101.98
Myriad Genetics promptly appealed this summary judgment decision to
the Federal Circuit. Fearing massive losses if their vast portfolios of
DNA patents were also found invalid, the pharmaceutical and
biotechnology industries strongly supported the appeal.
BRCA1 and BRCA2 genes and prevent others from further studying these genes without
getting a license and paying royalties. Myriad established a monopoly for the genetic test,
and currently there is no other way to test for the presence of BRCA mutations without
infringing the Myriad patent.”).
98
Ass’n for Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 181, 185 (S.D.N.Y.
2010).
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Before the Federal Circuit ruled on the appeal, one of the original
defendants, the United States (representing the USPTO), surprised
supporters and opponents of Myriad Genetics alike when it changed
sides to support, at least partially, positions of the ACLU. On October
29, 2010, the Department of Justice filed an amicus curiae brief on behalf
of the federal government—including erstwhile defendant, the USPTO—
arguing that “isolated but otherwise unaltered” human genes constitute
unpatentable subject matter because they are products of nature under
35 U.S.C. § 101.99 On July 29, 2011, a panel of three Federal Circuit
judges reversed much of Judge Sweet’s decision, and, in doing so,
reaffirmed the eligibility of isolated DNA sequences for patent
protection.100 Notwithstanding this latest change of fortunes for gene
patents, it is likely that the losing party, the Association for Molecular
Pathology, will appeal this decision to the United States Supreme Court.
If the Supreme Court does grant a writ of certiorari in this case, perhaps
pairing it with another case, Prometheus v. Mayo,101 in which it already
granted certiorari to consider the patent-eligibility of biotechnology
inventions, and given the new official position of the federal
government, a decision finding at least some categories of DNA
ineligible for patenting is possible.
The results of the recent trend to limit patents claiming DNA will not
be known until two things happen: the federal courts finally decide the
issues in Ass’n for Molecular Pathology v. Myriad Genetics and Prometheus v.
Mayo, and Congress finally decides on what, if any, statutory reforms it
supports. In the meantime, much uncertainty hovers over the future
viability, vitality, and value of DNA patents. Copyright protection for
DNA sequences offers an alternative.
IV. SYNTHETIC BIOLOGY
In its most optimistic conception, the field of synthetic biology
promises nothing short of a brave new world. As Michael Specter
observed in 2009, “[i]f the science truly succeeds, it will make it possible
to supplant the world created by Darwinian evolution with one created
by us.”102 However, the field has more modest immediate goals: “By
99
Brief for the United States as Amicus Curiae in Support of Neither Party, Ass’n for
Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (No. 20101406).
100
Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329
(Fed. Cir. 2011).
101
Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347 (Fed. Cir. 2010).
102
Michael Specter, A Life of Its Own: Where Will Synthetic Biology Lead Us?, THE NEW
YORKER, Sept. 28, 2009, at 57.
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using gene-sequence information and synthetic DNA, they are
attempting to reconfigure the metabolic pathways of cells to perform
entirely new functions, such as manufacturing chemicals and drugs.
Eventually, they intend to construct genes—and new forms of life—from
scratch.”103 The success of synthetic biology will largely depend on two
fundamental technologies whose very names suggest the relevance of
copyright: (1) reading DNA (via rapid and inexpensive sequencing); and
(2) writing DNA (via rapid and inexpensive synthesis). To the long
evolution of DNA concepts, from factor to particle to sequence to
information to program, synthetic biology has the added possibility of
viewing DNA as lego-like “BioBricks” that can be arranged and
rearranged at will to build new structures and functions. In addition,
synthetic biology has introduced the idea of biologists as creative
authors engaged in literally writing the future of the book of life
nucleotide by nucleotide.
A. Recombining
The methods of recombinant DNA developed by Cohen and Boyer
demonstrated that DNA from a foreign source organism could be
reliably spliced into the genome of a distinct host organism. They used
restriction endonucleases to create a gap in a eubacterial plasmid,
inserted foreign DNA into the gap, and used DNA ligase to splice the
plasmid and foreign DNA together. 104 By showing that DNA could be
recombined into arrangements not found in existing genomes, 105 Cohen
and Boyer opened the door to the deliberate design of new genomes.
The subsequent successful insertion of the human somatostatin gene into
a eubacterial genome amplified this possibility by demonstrating the
intercompatibility of DNA from very disparate phylogenetic sources. 106
These experiments and techniques heralded “the new era of ‘synthetic
biology’ where not only existing genes are described and analyzed but
also new gene arrangements can be constructed and evaluated.”107
B. Programming
Biologists have long used the metaphor of the computer program to
describe the function of DNA. Crick’s succinct formulation anticipated
Id. at 56 (emphasis added).
Stanley N. Cohen et al., Construction of Biologically Functional Bacterial Plasmids In Vitro,
70 PROC. NAT’L ACAD. SCI. 3240, 3240 (1973).
105
Id. at 3244.
106
E.g., Itakura et al., supra note 60, at 1056.
107
Waclaw Szybalski & Ann Skalka, Nobel Prizes and Restriction Enzymes, 4 GENE 181,
181–82 (1978).
103
104
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subsequent, more explicit, uses of the metaphor: “DNA makes RNA,
RNA makes protein, and proteins make us.”108 Jacob and Monod offered
a more direct formulation, suggesting that “the genome contains not
only a series of blue-prints, but a co-ordinated program of protein
synthesis and the means of controlling its execution.” 109 Bonner
completed the progression by describing the genome as a “master
programme constituted in turn of a set of subprogrammes or
subroutines.”110 To be accurate, these formulations of DNA as computer
programs depend on cells or organisms capable of reliably processing
and implementing the instructions of their DNA programs. While
natural organisms that have resulted from organic evolution may
present challenges in this regard, a goal of synthetic biology is to
introduce reliability and predictability through deliberate and careful
engineering. To this end, Arjun Bhutkar asserts that “[a] primary
objective of this nascent research area is to create a programmable
microorganism from scratch.”111
C. Engineering
What is currently called synthetic biology was once known as
biological engineering. In the 1930s, MIT appointed Professor Joseph
Warren Horton the inaugural head of “the newly created Department of
Biological Engineering.”112 Despite the farsightedness of its founders,
the Department changed its status at MIT several times. In 1998, the
successor to the Department became a division of the MIT School of
Engineering, and in 2005, it reemerged as an independent department. 113
In his 1958 acceptance speech of the Nobel Prize for Medicine, Edward L.
Tatum offered his vision of how biology might transform itself into
biological engineering:
With a more complete understanding of the functioning
and regulation of gene activity in development and
differentiation, these processes may be more efficiently
controlled and regulated, not only to avoid structural or

On Protein Synthesis, supra note 47, at 139.
Jacob & Monod, supra note 52, at 354.
110
JAMES BONNER, THE MOLECULAR BIOLOGY OF DEVELOPMENT 134 (1965).
111
Bhutkar, supra note 57, at 19, 20.
112
Gerald L. Zeitlin, Professor Joseph Warren Horton (1889–1967): Biological Engineer, 13 J.
MED. BIOGRAPHY, 39, 39 (2005).
113
Massachusetts Institute of Technology School of Engineering, WIKIPEDIA,
http://en.wikipedia.org/wiki/Massachusetts_Institute_of_Technology_School_of_Engine
ering (last modified July 2, 2011).
108
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metabolic errors in the developing organism, but also to
produce better organisms.
. . . [Understanding the genetic code] may permit the
improvement of all living organisms by processes which
we might call biological engineering. 114
In 2005, Drew Endy published a series of suggestions entitled
Foundations for Engineering Biology, which outlined how biology could
finally achieve its promise as an engineering discipline. 115 He proposed
three general principles: (1) standardization; (2) decoupling; and (3)
abstraction.116 Standardization required “the definition, description and
characterization of the basic biological parts, as well as standard
conditions that support the use of parts in combination and overall
system operation.”117 Decoupling would break larger problems into a set
of discrete and smaller problems that could be solved separately. Then,
once its constituent smaller problems had been solved, a larger problem
could be solved.118 Abstraction would involve separating biological
engineering problems into hierarchical levels of complexity (“abstraction
hierarchies”) and then reengineering basic biological structures and
functions into simpler components.119 Biological engineering would
produce standard biological parts capable of being combined into more
complex biological devices, which in turn could be combined into even
more complex biological systems.120
Work has already begun on producing biological parts. The Registry
of Standard Biological Parts “is a continuously growing collection of
genetic parts that can be mixed and matched to build synthetic biology
devices and systems.”121 As of June 22, 2011, the Registry contained
15,177 genetic parts consisting of deposited DNA sequences. 122
Furthermore, the International Open Facility Advancing Biotechnology
(“Biofab”) was founded in December 2009 “as the world’s first biological
design-build facility.”123 Funded by the National Science Foundation,
Edward Tatum, A Case History in Biological Research, NOBELPRIZE.ORG (June 30, 2011),
http://nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-lecture.html.
115
DREW ENDY, FOUNDATIONS FOR ENGINEERING BIOLOGY 449–53 (2005).
116
Id. at 450–52.
117
Id. at 450.
118
Id. at 451.
119
Id. at 451–52.
120
Id.
121
REGISTRY OF STANDARD BIOLOGICAL PARTS, http://partsregistry.org/Main_Page (last
visited June 30, 2011).
122
Statistics
Snapshot,
REGISTRY
OF
STANDARD
BIOLOGICAL
PARTS,
http://partsregistry.org/cgi/partsdb/Statistics.cgi (last visited June 30, 2011).
123
About the Biofab, BIOFAB, http://www.biofab.org/about (last visited June 30, 2011).
114
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“[o]nce fully operational the Biofab facility will be capable of producing
tens of thousands of professionally engineered, high-quality standard
biological parts each year.”124 Whether called biological engineering or
synthetic biology, a new kind of biology in which DNA is deliberately
designed, written, and authored has arrived.
V. COPYRIGHT PROTECTION FOR DNA125
Works of genetic authorship fit within the existing framework of
copyright law. Congress does not need to amend the Copyright Act
itself; rather, courts must recognize that DNA is already copyrightable
subject matter. In part, this testifies to the flexibility of the Copyright Act
itself. However, DNA is also a molecule with properties that uniquely
preadapt it to eligibility for copyright protection. It is composed of an
alphabet of nucleotides, A, G, T, and C, whose specific order creates
meaning in a polynucleotide sequence.126 The meaning that resides in
the order of nucleotides is information that is easily decipherable both to
the cells that harbor DNA and to human readers of nucleotide
sequences.
Sequences of DNA have yet to be widely recognized as eligible for
copyright protection. This necessitates consideration of several aspects
of copyright law that might seem to be hurdles for DNA. These include
the requirements of statutory subject matter, originality, authorship, and
expression. In addition, there are necessary review bars to copyright
eligibility, such as functionality. Some of the information in DNA is
indeed functional. Nevertheless, due to redundancy in the genetic code
and to stretches of apparently “junk” DNA, much opportunity exists for
meaning—and expression—outside of the context of function. The case
for DNA copyright, despite functionality, is bolstered by the eligibility of
computer software for copyright protection because of similarities
between DNA sequences and computer algorithms, such as their ability
to encode functions. Sequences of DNA, especially synthetic DNA,
Id.
See infra Part IV (expanding upon the discussion of DNA Copyright in Andrew W.
Torrance, Synthesizing Law for Synthetic Biology, supra note 1, at 642–48).
126
RNA is a biological molecule very similar to DNA. Instead of A, C, G, and T, RNA is
composed of A, C, G, and uracil (“U”). Although RNA sometimes forms the genome of
certain viruses, it more commonly acts as a messenger that carries information from DNA
for the synthesis of polypeptides (that is, messenger RNA (“mRNA”)), carries amino acids
to the site of polypeptide synthesis (transfer RNA (“tRNA”)), forms ribosomes (ribosomal
RNA (“rRNA”)), or resides in the cell nucleus (small nuclear RNA (“snRNA”)). The case
for copyright protection of RNA and amino acid sequences is very similar to that for DNA.
In the absence of specific differences, this article will use “DNA” as a shorthand for DNA,
RNA, and polypeptides.
124
125
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already fit within the eligibility requirements of the Copyright Act.
Recognition of this is the next step.
If recognized, copyright protection may offer an alternative to patent
protection. For example, copyright protection is capable of producing a
socially desirable balance of restricted and permissible uses of DNA
sequences. It achieves this balance by replacing the strict liability regime
of patent law with the more flexible fair use defense and the fostering of
a feasible open source regime.
A. History
A number of authors have already discussed the applicability of
copyright law to DNA sequences.127 Irving Kayton was the first to
address the issue in 1982. Initially, he assumed that DNA was
uncopyrightable. As he described, “every intellectual and emotional
prejudice, both sophisticated and primitive, to which he is subject
opposed coming to the conclusions finally reached.
Copyright
protection for engineered DNA sequences seemed ludicrous.” 128 Yet,
careful analysis of the Copyright Act changed his mind decisively.
Kayton summarized his conclusions as follows:
virtually all original works of a genetic scientist are
copyrighted automatically when he creates them; the
scientist generally can enforce his copyrights; those
copyrights may provide more effective protection than
other forms of intellectual property in many
circumstances; and copyright protection for genetically
engineered works appears within the constitutional
limits on Congressional power.129
Writing later in the decade, and with the benefit of a fuller flowering of
the biotechnology industry, Dan Burk also came to the conclusion that
DNA constituted subject matter eligible for copyright protection. Burk
suggested that copyright protection could extend “to encompass both
sequences of nucleotide bases and their written representation.” 130
E.g., Burk, supra note 7, at 469; Tani Chen, Can a Biological Sequence Be Copyrighted?,
INTELL. PROP. & TECH. L.J., Mar. 2007, at 1; Duncan M. Davidson, Common Law, Uncommon
Software, 47 U. PITT. L. REV. 1037, 1104–05 (1986); Kayton, supra note 6, at 191; Smith, supra
note 7, at 1096–1108; James G. Silva, Copyright Protection of Biotechnology Works: Into the
Dustbin of History?, B.C. INTELL. PROP. & TECH. F. (Jan. 28, 2000), http://www.bc.edu/
bc_org/avp/law/st_org/iptf/articles/content/2000012801.html.
128
Kayton, supra note 6, at 218.
129
Id. at 192.
130
Burk, supra note 7, at 496.
127
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Although not all analyses have supported the desirability of copyright
protection for DNA, none of the authors to consider this issue have
refuted its eligibility under the Copyright Act. Rather, these analyses
have tended to reject DNA copyrightability on grounds that either: (1)
the DNA sequences in question were natural in origin, and, thus, lacked
proper authorship or originality; or (2) public policy considerations,
rather than existing copyright law, militated against protection.
Furthermore, these previous analyses have not had the opportunity to
consider the impact of the recent field of synthetic biology, a field based
on the de novo design and construction of DNA under the direction of
human creativity. Where non-synthesized DNA may often be copyright
eligible, the arguments for copyright protection of synthetic DNA
sequences are a fortiori.
B. Requirements
Copyright protection applies to “original works of authorship fixed
in any tangible medium of expression, now known or later developed,
from which they can be perceived, reproduced, or otherwise
communicated, either directly or with the aid of a machine or device.” 131
Fixation can occur in any “form, manner, or medium.”132 However, the
mode of fixation must be “sufficiently permanent or stable to permit it to
be perceived, reproduced, or otherwise communicated for a period of
more than transitory duration.” 133 Since DNA is composed of stable
chemical nucleotides, DNA sequences should easily meet this
requirement.
Furthermore, DNA possesses definite sequences of
nucleotides that can easily be determined,134 copies of DNA may be
synthesized routinely and in effectively unlimited quantities, 135 and
molecular DNA has been known to last for at least many thousands of
years with its nucleotide sequence intact. 136 The authorship requirement
might pose a barrier to the copyrightability of genes and other DNA
sequences derived entirely from natural genomes. A challenge would be
posed by 17 U.S.C. § 102, which provides that “[c]opyright protection
subsists . . . in original works of authorship.” 137 By analogy, someone
17 U.S.C. § 102 (2006).
H.R. REP. NO. 94-1476, at 52 (1976).
133
17 U.S.C. § 101 (2006).
134
See, e.g., F. Sanger et al., DNA Sequencing with Chain-Terminating Inhibitors, 74 PROC.
NAT’L ACAD. SCI. U.S.A. 5463 (1977).
135
See, e.g., 2 JOSEPH SAMBROOK & DAVID W. RUSSELL, MOLECULAR CLONING: A
LABORATORY MANUAL 8.4 (3d ed. 2001).
136
See, e.g., Eske Willerslev & Alan Cooper, Ancient DNA, 272 PROC. ROYAL SOC’Y B. 3, 3–
5 (2005).
137
17 U.S.C. § 102 (2006).
131
132
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other than the author could not claim copyright protection for a
preexisting manuscript simply by discovering its existence.138 However,
synthetic biology can involve the design and construction of new,
human-designed DNA sequences. Here the synthetic biologist designs
the particular DNA sequence and “writes” it when she synthesizes it. 139
Since there is an author in this case, such DNA sequences should qualify
as “original works of authorship.”
Furthermore, although DNA
sequences lack the explicit statutory recognition as copyrightable subject
matter that computer software possesses, synthetic DNA sequences
should be eligible for copyright protection under the expansive
interpretation of “works of authorship” manifested by Congress in the
legislative history of the 1976 amendments to the Copyright Act. 140
Finally, DNA sequences can be “perceived, reproduced, or otherwise
communicated, either directly or with the aid of a machine or device.” 141
The genetic code of DNA is well understood by biologists, and DNA
sequences are easily reproduced.142 Furthermore, machines and routine
laboratory methods allow the specific nucleotides in DNA sequences to
be determined.143
Originality is another requirement of copyrightability. All sequences
of DNA are composed of existing nucleotides, each of which is
individually not new.
Some DNA sequences are “recombinant”
assemblages of existing nucleotide sequences ligated together. If the
focus of analysis were individual nucleotides or constituent sequences,
originality of DNA might be in question. However, in Roth Greeting
Cards v. United Greeting Cards Co., an analogous case of greeting cards
Of course, non-authors may obtain copyright protection through contractual means
for works authored by others.
139
In fact, fixing a DNA sequence via more conventional tangible forms of expression,
such as writing the nucleotide sequence down on paper, may also suffice.
140
See H.R. REP. NO. 94-1476, at 51 (1976) (describing the history of expansively
interpreting “works of authorship” to include new and varied forms of information).
The history of copyright law has been one of gradual expansion in the
types of works accorded protection, and the subject matter affected by
this expansion has fallen into two general categories. In the first,
scientific discoveries and technological developments have made
possible new forms of creative expression that never existed before. In
some of these cases the new expressive forms—electronic music,
filmstrips, and computer programs, for example—could be regarded
as an extension of copyrightable subject matter Congress had already
intended to protect, and were thus considered copyrightable from the
outset without the need of new legislation.
Id.
141
17 U.S.C. § 102.
142
See, e.g., SAMBROOK & RUSSELL, supra note 135, at 8.4–8.17.
143
See, e.g., Sanger et al., supra note 134, at 5463.
138
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whose constituent parts were not new, the court pointed out that the
“proper analysis of the problem requires that all elements of each
[work] . . . be considered as a whole. . . . Considering all of these
elements together, the Roth cards are, in our opinion, both original and
copyrightable.”144 Like greeting cards, recombinant or fully-synthetic
DNA sequences should be considered as a whole.
Under this
perspective, recombinant or synthetic DNA sequences are also likely to
qualify as original. Furthermore, novel nucleotides can also be used to
make nucleotide sequences. In 2011, geneticists Farren Isaacs, George
Church, and others developed a method of creating organisms with
genetic codes different from those of existing organisms. 145 Thus, not
only can synthetic biology create DNA sequences never before seen
outside the laboratory, entirely new genetic codes can be developed as
alternatives to existing codes based on DNA or RNA.
C. Subject Matter
There is no explicit mention of DNA sequences in 17 U.S.C. § 102,
nor do any of the eight enumerated categories of copyrightable subject
matter explicitly include DNA sequences. There are, however, several
significant respects in which DNA, genes, arrays of genes, and genomes
(not to mention their RNA and polypeptide products) fit within the
“literary works” category,146 both generally and as computer programs.
Like the English alphabet of twenty-six letters, DNA is composed of an
alphabet of four nucleotide “letters”: A, T, G, and C. 147 Triplets of these
nucleotide letters form “codons” that correspond to specific amino acids.
When strung together in a linear chain, amino acids comprise
polypeptides. A synthetic biologist can “write” strings of nucleotides
(for example, genes) in any pattern she wishes. Some patterns of
nucleotide letters could be written to produce specifically desired linear
chains of amino acids. At a higher level of organization, a synthetic
biologist could compose arrays of multiple synthetic genes in particular
patterns to produce complex results inside and outside of cells. Literary
works are defined in § 101 as “works . . . expressed in words, numbers,
429 F.2d 1106, 1109 (9th Cir. 1970). This case relied on the Copyright Act of 1909 and
was therefore superseded by the new Copyright Act. See Loree Rodkin Mgmt. Corp. v.
Ross-Simons, Inc., 315 F. Supp. 2d 1053, 1055 n.1 (C.D. Cal. 2004) (explaining that Ross did
not control that case because Ross relied on the 1909 Copyright Act which was amended by
the Copyright Act of 1976).
145
Farren J. Issacs et al., Precise Manipulation of Chromosomes in Vivo Enables Genome-Wide
Codon Replacement, 333 SCI. 348, 348353 (2011).
146
17 U.S.C. § 102 (2006).
147
A similar molecule, RNA, is composed of adenine, uracil (instead of thymine),
guanine, and cytosine. The RNA alphabet is A, U, G, and C.
144
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or other verbal or numerical symbols or indicia, regardless of the nature
of the material objects . . . in which they are embodied.”148 Nucleotides,
DNA, RNA, genes, amino acids, polypeptides, and proteins are certainly
“indicia,” and the letters used to denote nucleotides and amino acids, as
well as the codes used to denote genes may also qualify as
“verbal . . . symbols.”149 Furthermore, the statement “regardless of the
nature of the material objects . . . in which they are embodied” could
certainly include DNA or its related molecules. 150
Eligibility for copyright protection is not restricted to the seven
enumerated categories under § 102. Rather, the section introduces the
enumerated categories with the phrase “include[s] the following
categories.”151 In the “Definitions” section of the Copyright Act, § 101
explains that the “term[ ] ‘including’ . . . [is] illustrative and not
limitative.”152 The House Report accompanying the 1976 Copyright Act
reinforces this broad interpretation:
The use of the word “include,” as defined in [§] 101,
makes clear that the listing is “illustrative and not
limitative,” and that the seven categories do not
necessarily exhaust the scope of “original works of
authorship” that the bill is intended to protect. Rather,
the list sets out the general area of copyrightable subject
matter, but with sufficient flexibility to free the courts
from rigid or outmoded concepts of the scope of
particular categories.153
When considered in conjunction with the expansive phrase in § 102,
“any tangible medium of expression, now known or later developed,” 154
synthetic DNA sequences fit comfortably within the category of “literary
works.”155
D. Software
In 1974, the National Commission on New Technological Uses of
Copyrighted Works (“CONTU”) issued a report concluding that
“computer programs, to the extent that they embody an author’s original
148
149
150
151
152
153
154
155

17 U.S.C. § 101 (2006).
Id.
Id.
17 U.S.C. § 102.
17 U.S.C. § 101.
See H.R. REP. NO. 94-1476, at 53 (1976).
17 U.S.C. § 102.
Id.
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creation, are proper subject matter of copyright.” 156 The CONTU was
careful to distinguish copyrightable subject matter, such as creative
expression in computer software, from uncopyrightable subject matter,
such as “idea[s], procedure[s], process[es], system[s], method[s] of
operation, concept[s], principle[s], or discover[ies].”157 Moreover, it
emphasized that “one is always free to make the machine do the same
thing as it would if it had the copyrighted work placed in it, but only by
one’s own creative effort rather than by piracy.” 158 Formal recognition of
computer software as copyrightable subject matter occurred in 1980,
when Title 17 (the “Copyright Act”) was amended to include explicit
copyright protection for computer software. 159 Section 101 of the
Copyright Act defines “computer program” as “a set of statements or
instructions to be used directly or indirectly in a computer in order to
bring about a certain result.” 160 Although there are some special
limitations on the exclusive rights conferred to owners of copyrights on
computer software,161 this form of expression is now routinely protected
by copyright.
Synthetic biology is largely based on a conception of genes, cells, and
organisms as programmable. In a measured version of this conception,
Endy has suggested that “synthetic biology provides an opportunity to
test the hypothesis that the genomes encoding natural biological systems
can be ‘re-written,’ producing engineered surrogates that might usefully
supplant some natural biological systems.”162 However, as a more
ambitious articulation has portrayed it, “[a] primary objective of
[synthetic biology] is to create a programmable microorganism from
scratch,” 163 and it is increasingly possible to “program living organisms
in the same way a computer scientist can program a computer.” 164
Consequently, if computer software is copyrightable, perhaps “biological
software” is, or ought to be, as well.
It is relatively easy for a human mind to understand the “meaning”
of a DNA sequence. Once a proper reading frame has been determined

NAT’L COMM’N ON NEW TECHNOLOGICAL USES OF COPYRIGHTED WORKS, FINAL REPORT
COMMISSION ON NEW TECHNOLOGICAL USES OF COPYRIGHTED WORKS 1, 2
(1978) [hereinafter NAT’L COMM’N].
157
Id. at 18 (citing 17 U.S.C. § 102 (b)).
158
Id. at 21.
159
See H.R. REP. NO. 96-1307, pt. 1, at 23–24 (1980).
160
17 U.S.C. § 101 (2006).
161
17 U.S.C. § 117 (2006).
162
ENDY, supra note 115, at 449.
163
Bhutkar, supra note 57, at 20.
164
D.I.Y. Organisms, ECOPOLIS, http://www.ecopolis.org/diy-organisms/ (last visited
July 17, 2011).
156
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for the sequence,165 one only has to recognize triplets of nucleotides and
assign corresponding amino acids to each triplet. Thus, someone of
modest skill in genetics could examine a DNA sequence of 300 coding
nucleotides, in proper reading frame, and then determine the specific 100
amino acid sequence of its corresponding polypeptide. By contrast, it is
much more difficult for one of similar skill in computer software to
understand the “meaning” of either object code or source code. With
respect to computer software, both source code and object code are
eligible for copyright protection.166 Source code is a form of a computer
program expressed in a programming language understandable to
humans. Object code, by contrast, is a form of a computer program
expressed in binary (that is, “1s” and “0s”); object code cannot generally
be understood by the human mind. If object code is eligible for
copyright protection, then, a fortiori, so should DNA sequences because
they can be relatively easily understood.
Rather than portray DNA sequences as analogous to computer
software, a synthetic biologist (and copyright law) might actually
consider DNA sequences to be a form of computer software. A gene is a
set of instructions for producing a polypeptide. 167 A cell (or even an
organism), via the molecules, metabolic pathways, and signaling
pathways it contains, acts in response to the set of instructions encoded
in its genes to carry out a certain result. Thus, “a [gene encodes a] set of
statements or instructions to be used directly or indirectly in a [cellular]
computer in order to bring about a certain [metabolic or signaling]
result.”168 Given that one of the primary goals of synthetic biology is to
engineer cells and genes to become ever more like computers and
computer software, as synthetic biology succeeds in making DNA
appear more similar to computer software, DNA sequences will likely
move towards copyrightability by analogy to computer software.
165

LEWIN, supra note 15, at 860.
A reading frame is one of three possible ways of reading a nucleotide
sequence. Each reading frame divides the sequence into a series of
successive triplets. There are three possible reading frames in any
sequence, depending on the starting point. If the first frame starts at
position 1, the second frame starts at position 2, and the third frame
starts at position 3.

Id.
E.g., Apple Computer, Inc. v. Franklin Computer Corp., 714 F.2d 1240, 1248 (3d Cir.
1983).
167
LEWIN, supra note 15, at 852. “A gene is the segment of DNA specifying a polypeptide
chain.” Id.
168
Cf. 17 U.S.C. § 101 (2006) (showing how material about DNA sequences can fit into the
existing definition of computer software). The bracketed material is added to make this
point.
166
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Alternatively, if cells and organisms are already computers, and genes
are already software, then DNA sequences are already eligible for
copyright protection.
Whether or not cells are computers and genes are computer software
is largely an empirical question. Endy offers a number of examples,
including:
[a] DNA sequence that programmes a biofilm to take a
photograph and perform distributed edge-detection on
the light-encoded image . . . [a] DNA sequence that
programmes any mammalian cell to count up to 256 in
response to a generic input signal . . . [and a] DNA
sequence that programmes any prokaryote to produce
25 gl-1 artemisinic acid.169
However, rather than characterizing any of these examples as science
fiction or hopeful thinking, Endy notes that “each application is
physically plausible, or is the direct extension of an already
demonstrated result.”170 This suggests that synthetic biology is well on
the way towards cells as computers and genes as computer software.
The consequences for the copyrightability of synthetic DNA sequences
are significant.
E. Functionality
Copyright law limits protection to works of authorship that do not
monopolize a particular function. 171 If a DNA sequence of a synthetic
gene were to represent the only way of producing an RNA or
polypeptide with a particular function, then that sequence would not
likely possess strong copyright protection. However, if multiple DNA
sequences could produce the same RNA or polypeptide with a particular
function, then any one individual sequence would likely have much
stronger copyright protection. In addition, as long as a work of
authorship is original, it cannot infringe the copyright of another work of
authorship, even if the two works of authorship are identical. Thus,
even a copyright protecting a particular synthetic DNA sequence would
not prevent others from independently designing an identical or similar
DNA sequence. As a consequence, independent invention of identical or
similar synthetic DNA sequences would act as a counterbalance to any
ENDY, supra note 115, at 449.
Id.
171
See 2 MELVILLE B. NIMMER & DAVID NIMMER, NIMMER ON COPYRIGHT § 2.01[A]
(Matthew Bender, rev. ed., 2009).
169
170
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monopoly rights conferred on the first author. Copying would still
constitute copyright infringement, but independent invention would be
permissible. This would stand in stark contrast to the rights conferred
by patents claiming DNA sequences because the strict liability regime of
patent law does not relieve independent inventors from liability.
Patent law offers protection for functional creations. In fact, patent
law includes an explicit requirement that an invention possess utility in
order to be eligible for protection with a utility patent. 172 By contrast,
courts have often hesitated to confer copyright protection to utilitarian
works. In Baker v. Selden, the Supreme Court refused to endorse
copyright protection for an accounting system explained in an otherwise
copyrightable book entitled Selden’s Condensed Ledger of Bookkeeping
Simplified.173 In explaining why the blank forms in the book were
ineligible for copyright protection, the court stated that, “in using the
[accounting system], the ruled lines and headings of accounts [on the
blank forms] must necessarily be used as incident to it.” 174 In other
words, a work whose form is dictated solely by function is
uncopyrightable. However, the mere fact that a work possesses
functionality does not preclude it from copyright eligibility. To illustrate
this point, the book at issue in Baker v. Seldon was copyrightable. As long
as a work possesses adequate expression, it is eligible for copyright
protection—even if it possesses functionality. Thus, DNA molecules are
copyrightable to the extent their nucleotide sequences are not dictated by
function. If the expression of an idea in an otherwise copyright-eligible
work is entirely determined by functional considerations, copyright
protection is not appropriate because expression and idea may have
impermissibly merged. Some of the information in DNA is indeed
functional, but due to redundancy in the genetic code and to stretches of
apparently “junk” DNA, much opportunity exists for meaning—and
expression—outside of the context of function. This may be especially
true for synthetic DNA sequences. Synthesized strands of DNA may be
deliberately designed to lack function.175 They may be designed with
35 U.S.C. § 101 (2006).
Baker v. Selden, 101 U.S. 99, 100–01 (1880).
174
Id. at 104.
175
Press Release, J. Craig Venter Inst., First Self-Replicating Synthetic Bacterial Cell (May
20, 2010), available at http://www.jcvi.org/cms/press/press-releases/fulltext/article/firstself-replicating-synthetic-bacterial-cell-constructed-by-j-craig-venterinstitute-researcher/.
For commentary of Venter’s breakthrough, see Daniel G. Gibson et al., Creation of a Bacterial
Cell Controlled by a Chemically Synthesized Genome, 329 SCI. 52 (2010); Jonathan Khan,
Synthetic Hype: A Skeptical View of the Promise of Synthetic Biology, 45 VAL. U. L. REV. 1343,
1343 (2011); Kristine S. Knaplund, Synthetic Cells, Synthetic Life, and Inheritance, 45 VAL. U. L.
REV. 1361, 136263, 1366 (2011); Stephen M. Maurer, End of the Beginning or Beginning of the
End? Synthetic Biology’s Stalled Security Agenda and the Prospects for Restarting It, 45 VAL. U.
172
173
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function in mind, but may be expressed in many different permutations
of specific nucleotides and corresponding amino acids. Additionally,
some of their nucleotide positions (e.g., the first codon position) may be
fixed for reasons of function, while other nucleotides (e.g., the second
and third codon positions) are largely unfettered from functional
constraints. Furthermore, even functionality is not an absolute bar to
copyrightability for DNA sequences or other works. In fact, the
functionality threshold a nucleotide sequence must exceed to be eligible
for copyright protection is not high. Although some DNA molecules
whose sequences are strictly functionally constrained may not surmount
this threshold, many other less-constrained DNA molecules will not be
precluded from copyrightability on grounds of functionality.
In practical terms, very short sequences of DNA encoding very short
polypeptides would probably be uncopyrightable due to the very limited
number of sequences capable of encoding the corresponding amino
acids. Such sequences would likely lack sufficient expression for
copyrightability. Such a limitation on copyrightability would ensure
that short building-block sequences of DNA remained in the public
domain. To illustrate, this might cast doubt on the strength of copyright
protection that Illumina can expect for its oligonucleotides. 176 As DNA
sequences increase in length and complexity, however, their eligibility
for copyright protection would grow in proportion to their potential to
be expressed in multiple ways.177 Furthermore, DNA sequences having
little or no functionality and abundant expression, such as the “Shotgun
Wedding” puzzle in the 2005 MIT Mystery Hunt, would be readily
eligible for copyright protection. Synthetic DNA would be relatively
more likely than genomic DNA to qualify for copyright protection

L. REV. 1387, 139293 (2011); Thomas H. Murray, What Synthetic Genomes Mean for our
Future: Technology, Ethics, and Law, Interests and Identities, 45 VAL. U. L. REV. 1315, 1321,
1338 (2011); Eleonore Pauwels, Who Let the Humanists into the Lab?, 45 VAL. U. L. REV. 1447,
145456 (2011).
176
See supra Part I (explaining the potential of DNA copyright protection).
177
Burk, supra note 7, at 501. Dan Burk uses the example of relatively unconstrained
“enhancer control sequence,” observing that “[i]n the case of enhancers, the same function
may be achieved through many arrangements, and thus a particular arrangement may be
copyrightable.” Id. In a footnote to this sentence, Burk adds:
A closer question may be presented where elements are not absolutely
constrained by functional considerations, but simply arranged for the
sake of efficiency. If only one or a few arrangements are most efficient,
merger may again prevent their copyrightablility. Naturally, these
would be the arrangements innovators would most want to protect.
Id.
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because of its origin within a human design milieu rich in opportunities
for expressive choices.178
F.

Duration

A copyright term lasts substantially longer than a patent term. A
valid patent only lasts from the date it was issued until 20 years from the
United States filing date of its corresponding patent application. 179 For
most works of authorship created on or after January 1, 1978, the
copyright term for an individual author may last throughout the life of
that author plus 70 additional years, 180 while the term for anonymous
and pseudonymous works and works for hire last for the earlier of 75
years from publication or 100 years from creation. 181 The longer term of
a DNA copyright would increase the value of this right to its owner.
However, any deadweight loss caused by this monopoly right would
create long-term costs to society. Several features of copyright law
would act to lessen this burden, such as independent creation, fair use,
and the opportunities DNA copyright would create for open source
biology.
G. Independent Creation
Unlike the case in patent law, copyright law frees from liability
independently created works, which are identical to copyrighted works.
Copyright law simply requires independent creation.182 As long as a
work authored second in time is original and not copied, it does not
infringe an identical work created first in time. In fact, both works
would qualify for copyright protection. By contrast, even independently
created inventions can infringe a patent under the prevailing regime of
strict liability.
H. Fair Use
Unlike patent law, which applies a strict liability standard to
instances of infringement offering few and insubstantial exceptions,
Note that DNA sequences generated by computer software and lacking expressive
choices would have relatively less eligibility for copyright protection.
179
35 U.S.C. § 154(a)(2) (2006). There are minor variations to this term for patents that
reference priority documents under 35 U.S.C. § 120, § 121, and § 365(c). In addition, the
patent term may be extended under 35 U.S.C. § 154(b), § 155, § 155A, and § 156.
180
17 U.S.C. § 302(a). For joint authors, the term lasts 70 years beyond the death of the
last author to die. 17 U.S.C. § 302(b).
181
17 U.S.C. § 302(c).
182
17 U.S.C. § 101 (2006).
178
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copyright law includes a provision that explicitly allows several
significant uses of copyrighted works without resulting in liability for
infringement. Section 107 of the Copyright Act, entitled “Limitations on
exclusive rights: Fair use,” describes this safe harbor from copyright
infringement.183 It states:
the fair use of a copyrighted work, including such use by
reproduction in copies or phonorecords or by any other
means specified by [§ 106 and § 106A], for purposes
such as criticism, comment, news reporting, teaching
(including multiple copies for classroom use),
scholarship, or research, is not an infringement of
copyright.184
Several of these enumerated instances of fair use are highly relevant to
DNA sequences. Section 107 would appear to contemplate the copying
and use of copyrighted DNA sequences for educational purposes. For
example, biology professors and their students would seem permitted to
make “multiple copies” of copyrighted DNA sequences for use in their
studies of genetics in their classrooms and teaching laboratories. In
addition, scholars and researchers of genetics would appear to be able to
make and use copies of DNA sequences without triggering liability for
copyright infringement. For example, a geneticist could seemingly copy
and use copyrighted genes for her research, while, by contrast, such
activities would trigger strict liability under patent law if the genes in
question were claimed in a patent.
In addition to enumerated examples of copying that would not
constitute copyright infringement, § 107 requires a mandatory analysis of
four factors to determine “whether the use made of a work in any
particular case is a fair use.”185 These four factors are:
(1) the purpose and character of the use, including
whether such use is of a commercial nature or is for
nonprofit education purposes;
(2) the nature of the copyrighted work;
(3) the amount and substantiality of the portion used in
relation to the copyrighted work as a whole; and

183
184
185
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(4) the effect of the use upon the potential market for or
value of the copyrighted work.186
The relatively stronger case for fair use tends to occur when the copying
of the work is only partial and the context is noncommercial. Examples
might include when copyrighted DNA sequences are used
transformatively in scholarship or the DNA sequences are copied during
academic laboratory research. Alternatively, the relatively weaker case
for fair use tends to occur when the copying of the work is complete and
the context is commercial. Examples might include the wholesale
representation of complete nucleotide sequences of copyrighted DNA
molecules on a commercial website or the industrial replication of
copyrighted DNA sequences for sale at a profit.
Another exception to copyright infringement can be found in § 108,
which allows libraries and archives to make and lend a copy of a DNA
sequence as long as it is done in accordance with the other provisions of
the section.187
Patent law allows very few instances of copying to escape
infringement liability. Even the use of patented inventions in the
educational or research environments of universities can trigger patent
This strict liability regime may chill even
infringement.188
noncommercial activities, such as academic research, that would seem to
pose minimal economic threat to owners of patent rights. The fair use
defense in copyright creates a significant safe harbor within which
socially valuable activities, such as academic research, may survive and
perhaps, even thrive. Many critics and scientists who consider current
patent law too unforgiving to genetic research would welcome a
copyright regime with a robust fair use exception to infringement.
I.

Open Source Biology

Open source software has generated many valuable innovations.
These include Linux operating systems, Apache server software, and
Ruby on Rails database software. Much open source software is created
under the rubric of an open source license that relies on copyright law to
enforce its provisions. Though often proposed, open source biology has
thus far failed to make much of an impact on the field of biology. In
part, the failure of open source biology can be blamed on the difficulty of
adapting the patent system to an open source license. Unless all patent
rights are covered by an open source license—a virtual impossibility—
186
187
188

Id.
17 U.S.C. § 108 (2006).
Madey v. Duke, 307 F.3d 1351 (Fed. Cir. 2002).
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open source biology developers will fear the existence of patent liability
for their activities. However, were DNA sequences to be protected by
copyright rather than patent law, open source licenses could potentially
offer the same advantages to open source biology as they do to open
source software. If synthetic biology were indeed to make it technically
feasible to develop programmable genes and organisms, open source
biology licenses undergirded by copyright for DNA sequences could
help the field achieve its potential.
VI. CONCLUSION
Copyright law has traditionally afforded protection to works of
authorship such as books, magazines, photographs, paintings, music,
and sculpture. The Copyright Act has proved admirably flexible at
accommodating
novel
categories
of authorship, specifically
contemplating future developments by covering “original works of
authorship fixed in any tangible medium of expression, now known or
later developed.”189 This has led to explicit copyright protection for
nontraditional works of architecture and computer software. Sequences
of DNA should also be acknowledged as eligible for copyright
protection.
Unaltered genomic DNA sequences would seem poor candidates for
copyright protection. The case is stronger for copyright protection of
recombinant DNA sequences. Strongest is the case for the copyright
eligibility of synthetic DNA sequences designed nucleotide by
nucleotide and chemically constructed de novo. Whereas DNA copyright
has previously remained a largely hypothetical prospect, advances in
synthetic biology may now force recognition of copyright protection as
an alternative (or complement) to patent protection.
A DNA copyright regime would differ substantially from the current
DNA patent regime. Notably, acquiring copyright protection for DNA
would be less expensive and much more rapid than pursuing patent
protection. As patent law recognizes few and weak exceptions to
infringement, copyright law offers a robust fair use exception for
copying done in contexts such as scholarship and research. Furthermore,
copyright protection would be limited in the case of DNA molecules
whose structures are dictated by functional constraints, thus providing
the public greater and salutary access to useful genes.
Copyright protection for DNA lies pregnant within current
copyright law. What is required is an effort to make use of the existing
protection. A DNA copyright regime would not only allow a more
189
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robust set of safe harbors for use of particular DNA sequences, especially
in genetic research, it would also facilitate the possibility of an open
source biology movement. Finally, just as the prospects of patent
protection for at least some forms of DNA have become uncertain,
copyright protection could fill any resulting gap by affording a
reasonable level of intellectual property protection, while simultaneously
allowing society to enjoy some of the benefits of genetic knowledge more
freely than the current patent protection is able to afford.
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